- The Advisory Council met to guide the objectives of the next year for the Association, which will focus on the areas of professionals, patients and public administrations.
The Spanish Association of Biosimilar Medicines - BioSim has held the meeting of its Advisory Council, a body made up of various scientific societies, patient associations, health professional associations and professionals of recognized prestige that provide support for the purposes of the Association.
Dr. Antonio Zapatero, future president of the Federation of Spanish Medical Scientific Associations (FACME), has joined this meeting as the next member of the Council.
In relation to the actions that have been carried out during this year, the following stand out as the most significant:
- Actions to improve training among patients on biosimilar medicines through collaboration with various associations.
- Support for the need to perfect the mechanisms so that the public purchase of biological medicines takes into account quality criteria in addition to price.
- The promotion of transparency in drug selection criteria in health administrations.
- The areas of collaboration with health professional organizations (professional associations and scientific societies) for a better understanding of biosimilar medicines.
To this end, BioSim has developed activities aimed at maintaining a stable relationship framework with health administrations (in their national and regional spheres); sign various collaboration agreements and training activities with patient associations, scientific societies and professional associations; maintain a constant presence in discussion forums and scientific conferences on biosimilars and their strategic role in the pharmaceutical market; and edit various publications aimed at promoting the dissemination of knowledge about biosimilar medicines.
Lilines of work for 2020.
In relation to the new financial year of 2020, BioSim has considered reinforcing various actions that will be broken down successively into new activities. Among them, three fundamental lines stand out:
- Continue with training actions in cooperation with professional associations and scientific societies to generate and disseminate knowledge about biosimilar medicines and their contribution to the National Health System.
- Promote training and outreach actions for patients on biosimilar drugs, in collaboration with patient associations, aimed at increasing their confidence in these drugs.
- Continue working with health administrations, health managers, and political parties to value the biosimilar drug segment and the opportunities it opens up for health systems, as well as to achieve the appropriate regulatory framework for its development in the market.
